Free public records show Qilu Pharmaceutical Co., Ltd. in 19 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Qilu Pharmaceutical Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
107 active studies led by Qilu Pharmaceutical Co., Ltd., of 208 in all
Source: ClinicalTrials.gov, Studies with Qilu Pharmaceutical Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
17 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Studies Qilu Pharmaceutical Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Qilu Pharmaceutical Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Qilu Pharmaceutical Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Qilu Pharmaceutical Co., Ltd. is in.
Stories on the topics Qilu Pharmaceutical Co., Ltd. works in.
Anaemia affects about half a billion women worldwide, and folic acid before pregnancy prevents serious birth…
Read
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Sequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics…
ReadSearch all reports for Qilu Pharmaceutical Co., Ltd. All companies